Clinical Trial Update: Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update evaluating Trilaciclib (G1T28) to reduce chemotherapy-induced myelosuppression in patients with previously treated extensive-stage small …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Cosela (trilaciclib)
• Hycamtin (Topotecan)

Snippet

Sponsor: G1 Therapeutics, Inc. | Conditions: Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-06-09